Form 4: CME Group Director Reports Future Stock Sale

CME Group Inc. Director Dennis Suskind reported a future sale of 748 shares of Class A Common Stock at $300 per share, effective February 6, 2026.

Summary

• Dennis Suskind, a Director of CME Group Inc. (CME), filed a Form 4 reporting a transaction.
• The transaction involves the disposition of 748 shares of Class A Common Stock.
• The sale price for these shares is $300 per share.
• The transaction date is February 6, 2026, indicating a future planned sale.
• Following this reported transaction, Dennis Suskind will beneficially own 2,699 shares of Class A Common Stock.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly negative event. While a director's sale is generally seen as negative, the pre-planned nature under Rule 10b5-1(c) reduces its immediate signaling impact, suggesting personal financial planning rather than a reaction to company-specific news.

Positives

• NA

Negatives

• A director's sale of shares, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, though the Rule 10b5-1(c) plan mitigates this interpretation.

Risks

• NA

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely monitored by investors for signals regarding a company's future prospects. While a pre-planned sale under Rule 10b5-1(c) typically indicates a scheduled divestment rather than a reaction to new information, the market still scrutinizes such disclosures.

Stakeholder Impact

• Shareholders may view the director's sale with caution, although the pre-planned nature under Rule 10b5-1(c) suggests it is not a reaction to new negative information.

Key Dates

Recommendation

A single, pre-planned insider sale, especially one scheduled for a future date, typically does not warrant a change in investment recommendation unless accompanied by other significant company news or a pattern of widespread insider selling. Investors should monitor future filings and company performance for more definitive signals.

Keywords

CME Group, CME, Dennis Suskind, Form 4, Insider Trading, Stock Sale, Director Transaction, 10b5-1 Plan